Cancer has traditionally been diagnosed and monitored using imaging tests and tissue biopsies. While these tools are powerful, they can be invasive and may not always capture the full picture of how a cancer behaves over time. Scientists are now turning their attention to circulating tumor cells (CTCs)— which are tumor cancer cells found in the bloodstream—as a promising way to better detect, track, and understand cancer using a simple blood sample.
What Are Circulating Tumor Cells and Why Does This Matter?
Circulating tumor cells are cancer cells that break away from a primary tumor and enter the bloodstream. These cells can travel to other parts of the body and may later form new tumors, a process known as metastasis.
CTCs are extremely rare. In many cases, there may be only one tumor cell among billions of normal blood cells. Despite this, their presence is important because they provide direct evidence that cancer cells are moving through the body.
Unlike tumor tissue taken from a single location, CTCs can reflect cancer cells from many tumor sites at once. This makes them a valuable source of real-time information about how cancer is changing and spreading.
How CTCs Are Used in Cancer Care Today
CTCs already play a role in cancer research and are beginning to influence patient care. One of their most important uses is risk prediction. Studies show that patients with detectable CTCs often have a higher risk of cancer coming back or progressing.
CTCs can also help doctors understand how aggressive a cancer may be. In some cancers, higher CTC counts are linked with worse outcomes. This information may help guide decisions about treatment intensity or follow-up schedules.
In addition, CTCs allow researchers to study cancer biology in ways that are not possible with standard biopsies, including how cancer cells survive in the bloodstream and resist treatment.
CTCs vs Circulating Tumor DNA: What’s the Difference?
Both CTCs and circulating tumor DNA (ctDNA) are used in blood tests biopsies, but they provide different types of information.
- CTCs are whole, living cells. They contain DNA, RNA, and proteins, allowing scientists to study cell structure, gene activity, and surface markers.
- ctDNA consists of small DNA fragments released by dying cancer cells. It is easier to detect and is already widely used to find genetic mutations.
ctDNA tests are faster and more practical for routine use, but they lack the full biological detail found in intact cells. CTCs, while harder to isolate, offer deeper insight into cancer behavior, drug resistance, and cell-to-cell differences. The article emphasizes that CTCs and ctDNA are best used together, not as replacements for one another.
Using CTCs for Early Cancer Detection
CTCs may help identify cancer at very early stages—sometimes before tumors can be seen on scans. Research shows that CTCs can be detected in some patients with early-stage cancers and even after surgery when no visible cancer remains.
This makes CTCs a potential tool for identifying minimal residual disease, meaning tiny amounts of cancer that remain after treatment. Detecting these cells early could help doctors act sooner, possibly preventing recurrence.
However, the article also notes important limits. Because CTCs are so rare and difficult to isolate, they are not yet suitable for widespread cancer screening in the general population. Their future role may be as a follow-up test in high-risk patients or alongside other screening tools.
How CTCs Help Monitor Cancer Over Time
One of the most promising uses of CTCs is ongoing cancer monitoring. By testing blood samples over time, doctors can track changes in CTC numbers and characteristics.
CTCs can:
- Show whether a treatment is working
- Detect early signs of treatment resistance
- Reveal changes in cancer cell makeup before symptoms appear
Because CTCs reflect cancer cells from multiple tumor sites, they may provide a more complete picture than a single tissue biopsy. This could help doctors adjust treatments earlier and choose therapies that better match a patient’s current disease.
Looking Ahead: The Future of CTC-Based Testing
The article concludes that while CTCs are not yet used routinely in clinical care, rapid advances in technology are improving their detection and analysis. New tools that can study larger blood samples and analyze single cells in detail may soon unlock their full potential.
As cancer care becomes more personalized, CTCs may help doctors detect cancer earlier, monitor it more closely, and tailor treatments more precisely—all with a simple blood test.
Source:
Dai C, Dehm SM, Sharifi N. Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications. Cancer Cell. 2025;43(8):1-24. doi:10.1016/j.ccell.2025.07.008. Accessed By: https://rewriters.it/wp-content/uploads/2025/08/Blood_Based_Cancer_Detection_via_Circulating_Cells_1754282053.pdf
